Table 1.
Characteristics of patients in burst suppression and non-burst suppression groups
| Variable | Burst suppression group | Non-burst suppression group | P-valueb |
|---|---|---|---|
| n (%) | n (%) | ||
| Age (years) | 0.136 | ||
| < 30 | 5 (19.2) | 8 (32.0) | |
| 30–60 | 9 (34.6) | 12 (48.0) | |
| > 60 | 12 (46.2) | 5 (20.0) | |
| Sex | 0.068 | ||
| male | 16 (61.5) | 9 (36.0) | |
| female | 10 (38.5) | 16 (64.0) | |
| Etiology | 0.353 | ||
| encephalitis | 13 (50) | 10 (40.0) | |
| metabolic | 10 (38.5) | 8 (32.0) | |
| static lesion | 1 (3.8) | 5 (20.0) | |
| drug withdrawal | 2 (7.7) | 2 (8.0) | |
| History of epilepsy | 0.067 | ||
| yes | 7 (26.9) | 13 (52.0) | |
| no | 19 (73.1) | 12 (48.0) | |
| Number of antiepileptic drugs (before midazolam therapy) | 0.35 | ||
| 2 | 10 (38.5) | 5 (20.0) | |
| 3 | 11 (42.3) | 14 (56.0) | |
| 4 | 5 (19.2) | 6 (24.0) | |
| Status epilepticus severity score | 0.27 | ||
| 3 | 7 (29.9) | 12 (48.0) | |
| 4 | 15 (57.7) | 11 (44.0) | |
| > 4 | 4 (15.4) | 2 (8.0) | |
| Dose of midazolam (mg/kg/day) | 0.350 | ||
| < 0.6 | 10 (38.5) | 5 (20.0) | |
| 0.6–1.2 | 11 (42.3) | 14 (56.0) | |
| > 1.2 | 5 (19.2) | 6 (24.0) | |
| Time to midazolam therapy (hours) | 0.676 | ||
| ≤ 24 | 14 (53.8) | 12 (48.0) | |
| > 24 | 12 (46.2) | 13 (52.0) | |
| Length of hospital stay (days) | 0.747 | ||
| < 14 | 11 (42.3) | 8 (32.0) | |
| 14–21 | 9 (34.6) | 10 (40.0) | |
| > 21 | 6 (23.1) | 7 (28.0) | |
| Breakthrough seizure | < 0.001 | ||
| no | 19 (73.1) | 1 (4.0) | |
| yes | 7 (26.9) | 24 (96.0) | |
| Withdrawal seizure | 0.061 | ||
| no | 12 (46.2) | 18 (72.0) | |
| yes | 14 (53.8) | 7 (28.0) | |
| Pulmonary complication | 0.657 | ||
| no | 14 (53.8) | 15 (60.0) | |
| yes | 12 (46.2) | 10 (40.0) | |
| Cardiac complication | 0.789 | ||
| no | 20 (76.9) | 20 (80.0) | |
| yes | 6 (23.1) | 5 (20.0) | |
| Fever/infection | 0.301 | ||
| no | 14 (53.8%) | 17 (68%) | |
| yes | 12 (46.2%) | 8 (32%) | |
| In-hospital mortality | 0.029 | ||
| alive | 12 (46.2) | 19 (76.0) | |
| dead | 14 (53.8) | 6 (24.0) | |
| Functional outcome at 3 monthsa | 0.379 | ||
| good | 7 (58.3) | 8 (42.1) | |
| poor | 5 (41.7) | 11 (57.9) |
aexcluding dead patients
bChi-square test